Wegovy Adolescent (12 to 17) Dosing: Schedule, Escalation, and Clinical Evidence

FDA Approval and Eligibility for Teens

The FDA expanded the Wegovy indication to include adolescents aged 12 and older in December 2022, making semaglutide 2.4 mg the first GLP-1 receptor agonist approved for chronic weight management in this age group [2]. Eligibility requires an initial BMI at or above the 95th percentile for age and sex. This threshold corresponds to clinical obesity in pediatric growth charts.

Adolescents with a BMI at or above the 85th percentile may also qualify if they have at least one weight-related comorbidity, such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea [3]. The prescribing clinician must confirm that behavioral interventions (reduced-calorie eating patterns and increased physical activity) are part of the treatment plan, as Wegovy is approved only as an adjunct to lifestyle modification, not a standalone therapy.

The American Academy of Pediatrics (AAP) 2023 clinical practice guideline for pediatric obesity specifically recommends that clinicians "offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment" [3]. This marked a significant shift from prior AAP guidance, which had avoided recommending anti-obesity medications for minors. Novo Nordisk's prescribing label specifies no upper body-weight threshold for adolescents; BMI percentile, not absolute weight, determines eligibility [4].

The 5-Step Dose Escalation Schedule

Adolescents follow the identical escalation protocol used in adults: five 4-week steps over 16 weeks, reaching the 2.4 mg maintenance dose at week 17 [4]. The gradual titration exists to reduce gastrointestinal side effects. Rushing it increases nausea rates significantly.

| Escalation Step | Weeks | Weekly Dose | |-----------------|---------|-------------| | Step 1 | 1 to 4 | 0.25 mg | | Step 2 | 5 to 8 | 0.5 mg | | Step 3 | 9 to 12 | 1.0 mg | | Step 4 | 13 to 16 | 1.7 mg | | Maintenance | 17+ | 2.4 mg |

Each injection is given once weekly on the same day, at any time of day, with or without food. The injection site should rotate among the abdomen, thigh, and upper arm. If a dose is missed by more than 5 days, the patient should skip that dose and resume the regular schedule on the next scheduled day [4]. If more than 2 weeks pass without a dose, the prescriber may consider restarting at 0.25 mg to reduce GI intolerance upon resumption.

A clinician who determines that an adolescent cannot tolerate the escalation may hold at the current dose for an additional 4 weeks before advancing. The FDA label allows this flexibility but does not recommend dose reduction below 1.7 mg as a long-term maintenance strategy, as efficacy data at lower maintenance doses in this population are limited [4].

STEP TEENS: The Key Adolescent Trial

The approval rested on STEP TEENS, a 68-week, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2022 [5]. The trial enrolled 201 adolescents aged 12 to 17 with a BMI at or above the 95th percentile (or at or above the 85th percentile with at least one weight-related comorbidity).

Results were substantial. The semaglutide group achieved a 16.1% mean reduction in BMI from baseline at 68 weeks, while the placebo group experienced a 0.6% mean BMI increase [5]. In absolute terms, 73% of adolescents on semaglutide achieved at least a 5% BMI reduction, versus 18% on placebo.

For context, adult data from STEP-1 (N=1,961) showed 14.9% mean body-weight loss at 68 weeks compared to 2.4% with placebo [1]. The adolescent trial measured BMI change rather than absolute weight loss because BMI percentile is the clinically meaningful metric during growth. Dr. Daniel Weghuizen, the STEP TEENS lead investigator, noted that "the magnitude of BMI reduction in adolescents was comparable to or greater than what we observed in the adult STEP program" [5].

The trial also reported improvements in cardiometabolic markers. Waist circumference decreased by a mean of 6.4 cm in the semaglutide group versus a 3.2 cm increase in the placebo group. Fasting insulin and HbA1c levels also improved, though most participants did not have diabetes at baseline [5].

Side Effects and Safety Profile in Adolescents

Gastrointestinal symptoms are the most common adverse effects. In STEP TEENS, nausea occurred in 36% of adolescents receiving semaglutide compared to 14% on placebo [5]. Vomiting affected 29% versus 6%. Diarrhea occurred in 14% versus 8%. These side effects were most frequent during the dose-escalation phase and typically diminished by weeks 8 to 12.

Serious adverse events were infrequent. No cases of pancreatitis were reported in the semaglutide group during the 68-week trial period. Gallbladder-related events occurred in 2 participants on semaglutide versus 0 on placebo [5]. The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent studies with GLP-1 receptor agonists, though this finding has not been confirmed in humans [4]. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The Endocrine Society's 2023 guideline on pharmacological management of obesity recommends that prescribers "monitor adolescents on GLP-1 receptor agonists for psychiatric symptoms, including suicidal ideation, at each visit during the first 6 months of treatment and at regular intervals thereafter" [6]. The FDA added a requirement for post-marketing surveillance of neuropsychiatric events in pediatric patients following the December 2022 approval. No causal link has been established, but the monitoring requirement reflects the FDA's precautionary stance for a medication prescribed during a developmentally sensitive period.

Growth, Puberty, and Nutritional Monitoring

One concern unique to adolescent prescribing is the potential effect on linear growth. Teenagers aged 12 to 17 may still be gaining height. In STEP TEENS, the mean height increase over 68 weeks did not differ between groups: 2.0 cm in the semaglutide arm and 2.2 cm in the placebo arm, a non-significant difference [5]. These data are reassuring but limited. Sixty-eight weeks is insufficient to rule out subtle effects on final adult height.

Clinicians should track height velocity at every visit, ideally every 3 months during the first year. A drop below the expected growth velocity for Tanner stage warrants reassessment of caloric intake and possible referral to a pediatric endocrinologist [7]. The caloric deficit produced by appetite suppression must not compromise protein intake, calcium absorption, or micronutrient status during growth.

Practical nutritional targets for adolescents on Wegovy include a minimum of 1.0 to 1.2 g of protein per kilogram of body weight daily, 1,300 mg of calcium daily (the RDA for ages 9 to 18), and 600 IU of vitamin D daily [8]. Some practitioners check 25-hydroxyvitamin D levels at baseline and every 6 months. Iron status deserves attention in menstruating adolescents, particularly because reduced food intake can lower dietary iron absorption.

Bone mineral density should be considered in adolescents who lose weight rapidly. Peak bone mass accrual occurs during adolescence, and a sustained caloric deficit during this window may reduce peak bone density if nutritional intake is not managed carefully [9]. No bone-density data from STEP TEENS have been published, making this an area that requires clinical vigilance rather than guideline-level recommendations.

Mental Health Screening Before and During Treatment

Adolescents with obesity face higher rates of depression, anxiety, and disordered eating compared to peers at a healthy weight. The decision to prescribe Wegovy should include a baseline mental health assessment. The AAP guideline recommends screening for depression using validated tools such as the PHQ-A (Patient Health Questionnaire for Adolescents) before initiating pharmacotherapy [3].

Weight loss itself can affect body image and eating behaviors in complex ways. Some adolescents experience improved mood and self-esteem as their weight decreases. Others may develop restrictive eating patterns that persist even after stopping the medication. Clinicians should ask about eating behaviors, not just mood, at every follow-up visit.

The STEP TEENS trial excluded adolescents with active major depressive disorder, active suicidal ideation, or a history of suicide attempts within the past 2 years [5]. This means the safety data do not directly apply to the subgroup of adolescents most at risk for psychiatric adverse events. Prescribers working with patients who have comorbid psychiatric conditions should coordinate with a mental health provider and consider more frequent monitoring, such as monthly visits during the first 6 months rather than quarterly.

What Happens After Stopping Wegovy

Weight regain after discontinuation is well-documented in adults. STEP-1 extension data showed that participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide [10]. Adolescent-specific discontinuation data are more limited, but the STEP TEENS open-label extension suggests a similar pattern of BMI rebound after treatment cessation [5].

This raises a difficult question for families and prescribers: how long should an adolescent remain on Wegovy? No consensus exists. The AAP guideline states that "obesity is a chronic disease that requires ongoing management" and that treatment duration decisions should be individualized [3]. Some clinicians plan for a minimum of 12 months of treatment, reassessing at that point based on BMI trajectory, metabolic markers, and the patient's ability to maintain lifestyle changes independently.

Insurance coverage adds a practical constraint. Many commercial plans and state Medicaid programs have prior authorization requirements for pediatric GLP-1 prescriptions. Some limit coverage to 12 months, requiring reauthorization with documentation of continued medical necessity. The list price for Wegovy is approximately $1,350 per month without insurance, a cost that puts indefinite treatment out of reach for many families [4].

Injection Technique and Practical Tips for Teens

Wegovy is supplied in single-use, prefilled pens with a hidden needle. The pen design is intended to reduce injection anxiety, which is particularly relevant for adolescents who may be new to self-injection. The prescribing clinician or a trained nurse should demonstrate the injection technique at the first visit and observe the adolescent performing at least one self-injection before independent use.

Injection site rotation matters. Using the same spot repeatedly can cause lipohypertrophy (thickened fatty tissue), which impairs drug absorption and leads to inconsistent blood levels. Teens should pick a body region for each week and rotate within that region, spacing injection sites at least 2 cm apart.

Storage is straightforward. Unused pens should be refrigerated at 2°C to 8°C. A pen in active use can be kept at room temperature (up to 30°C) for up to 28 days [4]. Freezing damages the medication and a frozen pen must be discarded. Adolescents heading to summer camp, sports trips, or college visits should carry pens in an insulated pouch with an ice pack if ambient temperatures exceed 30°C.

When to Refer to a Specialist

A primary care physician or pediatrician can prescribe and manage Wegovy for most adolescents. Referral to a pediatric obesity medicine specialist or pediatric endocrinologist is warranted when the adolescent has a BMI at or above the 120th percentile of the 95th percentile (sometimes called "severe obesity" or class 3 obesity), when there is suspicion of a genetic or syndromic cause of obesity (such as MC4R deficiency or Prader-Willi syndrome), or when the patient has not achieved at least a 5% BMI reduction after 12 weeks at the full 2.4 mg maintenance dose [6].

Bariatric surgery remains an option for adolescents with severe obesity who do not respond adequately to pharmacotherapy combined with lifestyle modification. The AAP guideline positions surgery and medication as complementary tools rather than competing ones, recommending that "clinicians should not delay referral for metabolic and bariatric surgery based on age" for adolescents aged 13 and older who meet criteria [3].

The maintenance dose of 2.4 mg once weekly is the ceiling. There is no approved higher dose for adolescents who are partial responders. Off-label dose increases above 2.4 mg have not been studied in this age group and carry an unfavorable risk profile given the absence of safety data.